Market Brief: Tissue-Engineered Wound Care Market Expected To Reach $1.9Bn By 2024 Amid Rising Chronic Disease
The skin replacement market is led by three key players who have all been impacted by COVID-19, but the sector may see a quicker rebound than others as treatments cannot be deferred for a long time.
You may also be interested in...
Wound care company MiMedx has raised $150m in private equity and debt financing from EW Healthcare Partners and Hayfin Capital Management. The funds will be used to scale commercialization of the company’s amniotic tissue products.
Truvian Sciences will use the proceeds to fund regulatory submission for its POC testing system in Europe and the US with hopes to bring to retailers, pharmacies, health systems in 2022.
ReWalk plans to use the proceeds to fund sales, R&D and reimbursement expenses related to its ReStore and Personal 6.0 devices as it continues to face negative effects of pandemic.